Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00183651 · ClinicalTrials.gov registry record · Phase 2

Treatment of Suicidal Women With Borderline Personality Disorder

A Phase 2 study of Suicide and Borderline Personality Disorder, sponsored by University of Washington.

Completed
Registry status
Phase 2
Development phase
99
Enrollment target
1
Study location

NCT00183651: Completed Phase 2 study of Suicide and Borderline Personality Disorder, sponsored by University of Washington.

NCT00183651 is a Phase 2 study of Suicide and Borderline Personality Disorder that has completed, run by University of Washington. The registered enrollment target is 99 participants, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00183651, a Phase 2 study of Suicide and Borderline Personality Disorder, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 2
Development phase
99 participants
Enrollment target
1
Study location

Study Summary

This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.

Interventions

  • BEHAVIORAL Standard dialectical behavior therapy (SDBT)
  • BEHAVIORAL Individual DBT with no DBT group sessions (DBT-I)
  • BEHAVIORAL Group Skills DBT with no DBT individual sessions (DBT-S)

Study Locations (1)

Washington

  • University of Washington, Department of Psychology, Behavior Research and Therapy Clinics - Seattle

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2004-04
Est. Completion 2010-06
Phase Phase 2
University of Washington

1,048 total trials

What the finished NCT00183651 record still lists

NCT00183651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Suicide appearing as the primary indexed condition, and to 3 interventions - of which Standard dialectical behavior therapy (SDBT) is the first listed.

NCT00183651 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT00183651 about?

NCT00183651 is a clinical study titled "Treatment of Suicidal Women With Borderline Personality Disorder". This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.

What is the current status of trial NCT00183651?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2004-04. Estimated completion is 2010-06.

What conditions does trial NCT00183651 study?

This clinical trial studies the following conditions: Suicide, Borderline Personality Disorder.

What interventions are being tested in trial NCT00183651?

The interventions under investigation include: Standard dialectical behavior therapy (SDBT) (BEHAVIORAL), Individual DBT with no DBT group sessions (DBT-I) (BEHAVIORAL), Group Skills DBT with no DBT individual sessions (DBT-S) (BEHAVIORAL).

Who is sponsoring clinical trial NCT00183651?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00183651 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Suicide

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00183651's enrollment target sits among peer trials

99 51st of 92 higher than 42 of 92 other Suicide trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00183651, the US trial registry maintained by the National Library of Medicine. NCT00183651 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.